NASDAQ$AURA

Aura Biosciences Inc · Q2 2025 earnings

Q2 2025 earnings · · Before market open · Investor relations

Briefing

Aura Biosciences reported Q2 2025, net income of $27.02B.

For Q2 2025, Aura Biosciences reported net income of $27.02B. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.

  • Net income $27.02B.
  • Aura Biosciences highlights operating priorities and capital allocation.
  • Aura Biosciences highlights operating priorities and capital allocation.

Headline financials

Total Revenue

$0.00

No prior period
EPS (adj)

-$0.47

No prior period
R&D Expenses

$22.9M

No prior period
G&A Expenses

$5.73M

No prior period
Interest Income

$1.68M

No prior period
Other Expense

$36K

No prior period
Income Tax Provision

$48K

No prior period
Avg. Shares Outstanding

58.0M

No prior period
Unrealized Loss on Securities

$88K

No prior period
Currency Adjustment

$8K

No prior period
Net Income

$27B

No prior period
Operating Income

-$28.6M

No prior period

Revenue & EPS history

Aura Biosciences · Revenue · Quarterly

$0

Q2 2025

Forward guidance

The release discusses Aura Biosciences's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.

Tailwinds

  • Aura Biosciences cites demand and execution supporting the near-term outlook.
  • Liquidity and balance-sheet capacity support operations and shareholder returns.

Headwinds

  • Macro, input costs, and FX may pressure margins quarter to quarter.
  • Segment mix and one-time items can affect comparability versus prior periods.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 16 quarterly earnings reports · overlaid with Q2 2025

Historical avgQ2 2025

+1.3%

Avg return

Earnings day

+0.3%

Avg return

5 days after

-7.0%

Avg return

30 days after

44%

8 / 18 earnings

Positive

+26.0%

Q3 2021

Best reaction

-8.9%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-3.1%-5.5%-24.3%
Q3 2025-0.7%-2.9%+17.4%
Q2 2025+4.2%-3.6%-11.0%
Q1 2025+1.9%-0.5%+6.8%
Q4 2024-6.7%-15.5%-23.2%
Q3 2024-7.3%-15.0%-24.2%
Q1 2024-1.1%+1.9%+1.6%
Q4 2023+2.9%+1.7%-5.4%
Q3 2023+4.5%+8.6%+18.9%
Q2 2023-8.9%-8.8%-16.4%
Q1 2023+0.5%+7.3%+22.4%
Q4 2022-1.0%-1.0%-15.6%
Q3 2022+10.1%+16.4%+4.4%
Q2 2022-0.5%-2.6%-19.0%
Q1 2022+4.9%+8.1%-4.5%
Q2 2021-1.5%+8.7%-21.4%
Q4 2021-1.5%+8.7%-21.4%
Q3 2021+26.0%-1.1%-10.6%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro